High-throughput viable circulating tumor cell isolation using tapered-slit membrane filter-based chipsets in the differential diagnosis of ovarian tumors

• Published in: PloS one Vol. 19; no. 6; p. e0304704
• Main Authors: Kim, Nam Kyeong, Suh, Dong Hoon, Kim, Kidong, No, Jae Hong, Kim, Yong Beom, Kim, Minki, Cho, Young-Ho
• Format: Journal Article
• Language: English
• Published: San Francisco Public Library of Science 04.06.2024
• Subjects: Antigens; Ascites; Benign; Blood; Cancer; Chemotherapy; Chip sets (Computers); Chips (electronics); Comparative analysis; Computed tomography; Cytokeratin; Diagnosis; Diagnostic systems; Differential diagnosis; FDA approval; Magnetic resonance imaging; Medical diagnosis; Medical prognosis; Medicine and Health Sciences; Membrane filters; Membranes; Metastasis; Ovarian cancer; Patients; Performance evaluation; Physical properties; Prostate; Research and Analysis Methods; Surgery; Tumor cells; Tumors; United States > US
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0304704

To evaluate the diagnostic performance of circulating tumor cells (CTCs) using tapered-slit membrane filter (TSF)-based chipsets for the differential diagnosis of adnexal tumors. A total of 230 women with indeterminate adnexal tumors were prospectively enrolled. The sensitivity, specificity, and accuracy of the CTC-detecting chipsets were analyzed according to postoperative pathological results and compared with those of cancer antigen (CA)-125 and imaging tests. Eighty-one (40.3%) benign tumors, 31 (15.4%) borderline tumors, and 89 (44.3%) ovarian cancers were pathologically confirmed. The sensitivity, specificity, and accuracy of CTC-detecting chipsets (75.3%, 58.0%, and 67.1%) for differentiating ovarian cancer from benign tumors were similar to CA-125 (78.7%, 53.1%, and 66.5%), but lower than CT/MRI (94.2%, 77.9%, and 86.5%). "CTC or CA125" showed increased sensitivity (91.0%) and "CTC and CA-125" revealed increased specificity (77.8%), comparable to CT/MRI. CTC detection rates in stage I/II and stage III/IV ovarian cancers were 69.6% and 81.4%, respectively. The sensitivity to detect high-grade serous (HGS) cancer from benign tumors (84.6%) was higher than that to detect non-HGS cancers (68.0%). Although the diagnostic performance of the TSF platform to differentiate between ovarian cancer and benign tumors did not yield significant results, the combination of CTC and CA-125 showed promising potential in the diagnostic accuracy of ovarian cancer.